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Dermal eccrine cylindroma and (less specific) 
cylindroma 




Dermal cylindroma is a common benign adnexal tumor 
which occurs mainly in the head and neck region, 
especially on the scalp and face (Weedon, 2002; 
McNiff et al., 2006). 
Clinics 
There is a strong predilection for middle-aged and 
elderly females. Dermal cylindromas may be found as 
solitary or multiple lesions, the latter being associated 
with the autosomal dominant Brooke-Spiegler 
syndrome (familial cylindromatosis; OMIM 605041) 
which is caused by mutations in the tumor suppressor 
gene CYLD (Bignell et al., 2000). 
Pathology 
Microscopically, dermal cylindromas are composed of 
multiple tumor lobules arranged in a jigsaw pattern. 
The lobules are typically surrounded by a rim of PAS-
positive basement membrane material and are 
composed of undifferentiated basaloid tumor cells. The 
histogenesis of dermal cylindroma is controversial. It is 
still uncertain whether they originate from apocrine or 
eccrine sweat glands or if they as recently suggested  
may be derived from hair follicle epithelium (reviewed  
 
in Weedon, 2002; Klein et al., 2005; Massoumi et al., 




Genes involved and proteins 
MYB (v-myb myeloblastosis viral 




Leucine zipper transcription factor. MYB in solid 
tumors was recently reviewed by Stenman et al., 2010. 
DNA / RNA 
RefSeq DNA sequence: NC_000006.11, 
NT_025741.15. 
Protein 
The MYB protein plays an essential role in the 
regulation of hematopoiesis and may play a role in 
tumorigenesis.  
Alternative splicing results in multiple transcript 
variants. 




CCAAT-box-binding transcription factor. 
DNA / RNA 
RefSeq DNA sequence: NC_000009.11, 
NT_008413.18. 
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RT-PCR analysis revealed that 6 of 11 dermal 
cylindromas were positive for the MYB-NFIB fusion; 
one case had a fusion of MYB exon 12 to NFIB exon 9 
and 5 cases had a fusion of MYB exon 14 to NFIB 
exon 8c. The composition of the chimeric transcript 
variants identified was identical to that previously 
reported in adenoid cystic carcinoma, suggesting a 
similar molecular mechanism of activation of MYB in 
both tumor types (Persson et al., 2009; Brill et al., 
2011; Fehr et al., 2011). 
Detection 
Described by Persson et al., 2009 and Fehr et al., 2011. 
Fusion Protein 
Description 
Analysis of MYB expression by immunohistochemistry 
using a monoclonal anti-MYB antibody recognizing an 
N-terminal peptide of the protein revealed 
overexpression of MYB in 6 of 10 cylindromas. 
Fusion-negative tumors lacked MYB expression, 
indicating that a subgroup of cylindromas in fact are 
MYB-negative (Fehr et al., 2011). 
To be noted 
Note 
The results from Fehr et al., 2011 indicate that MYB 
oncogene activation through gene fusion is an 
important pathogenetic mechanism that may contribute 
to cylindroma tumorigenesis. In this context it will be 
of interest to test also familial cases of cylindroma 
(Brooke Spiegler syndrome) for the MYB-NFIB fusion 
to determine whether MYB activation along with loss 
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